Trastuzumab: WHO Approved First Biosimilar Medicine for Breast Cancer

  • The World Health Organization (WHO) prequalified its first biosimilar medicine – trastuzumab – for treatment of breast cancer. The medicine, supplied by Samsung Bioepis NL B.V. (Netherlands), was assessed by WHO and found comparable to the originator product in terms of efficacy, safety and quality.
  • WHO Prequalification is a service provided by WHO to assess the quality, safety and efficacy of those products that address global public health ....
Do You Want to Read More?
Subscribe Now

To get access to detailed content

Already a Member? Login here


Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material before the last six months of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.

Related Content